Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689877 | 0.74 | HCRTR1 (0.46) | HCRTR1HCRTR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17846619 | 0.73 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL24271758 | 0.71 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17858035 | 0.71 | CKS1B (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL23302997 | 0.70 | HTT (0.50) | HCRTR1HCRTR2HTT | |
| SCHEMBL12870953 | 0.69 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL17858033 | 0.69 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL23568396 | 0.69 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL19689878 | 0.68 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL12295196 | 0.68 | HCRTR1 (0.42) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885CREBBP 591/4885 |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885CREBBP 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.